logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

< Back

Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Drugs

Cardiovascular Disease and Vascular Surgery

December 2017


Rivaroxaban and aspirin are drugs that reduce blood clots in blood vessels and are currently being given to some patients with CAD and PAD. The combination of rivaroxaban with aspirin is being developed as a more effective treatment. If licensed, this combination will offer a new option for the prevention of major cardiovascular events.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Rivaroxaban for Prevention of Cardiovascular Events



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts